Liquidia Technologies, Inc. (LQDA) News
Filter LQDA News Items
LQDA News Results
|Loading, please wait...|
LQDA News Highlights
- LQDA's 30 day story count now stands at 2.
- Over the past 8 days, the trend for LQDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest LQDA News From Around the Web
Below are the latest news stories about Liquidia Corp that investors may wish to consider to help them evaluate LQDA as an investment opportunity.
MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to the grantee’s acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the gra
We feel now is a pretty good time to analyse Liquidia Corporation's ( NASDAQ:LQDA ) business as it appears the company...
In a report released today, Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $12.00. The company's shares closed last Friday at $6.26. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 1.3% and a 38.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Liquidia Technologies with a $7.75 average price target. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.
Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Biohaven Pharmaceutical Holding Co (BHVN) and Liquidia Technologies (LQDA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CareDx (CDNA – Research Report), Biohaven Pharmaceutical Holding Co (BHVN – Research Report) and Liquidia Technologies (LQDA – Research Report). CareDx (CDNA) H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx today. The company's shares closed last Thursday at $40.19, close to its 52-week low of $39.16. According to TipRanks.
MORRISVILLE, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at closing. Liquidia initially entered a debt facility with SVB in March 2021 that provided up to $20.5 million in term loans of which $10.5 million had been funded to date. Under the terms of the new debt
The new CEO previously led United Therapeutics, which is currently in the midst of a legal battle with Liquidia.
MORRISVILLE, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director of the Company and will provide transition support through January 31, 2022. “Roger is a talented leader with incredible knowledge and experience in drug development and commercializing rare disease drug
A pharmaceutical company with a headquarters in Research Triangle Park claims a former employee took confidential information with him to a drugmaker based in Morrisville.
Liquidia (NASDAQ:LQDA) shareholders are a happy bunch, and there are good reasons for that. It’s worth noting that this biopharmaceutical company’s stock price has increased about 78% in the past three months. Positive developments, including the favorable court ruling in the ongoing patent dispute with United Therapeutics (UTHR), and the U.S. FDA’s (Food and Drug Administration) tentative approval for its Yutrepia (treprostinil) inhalation powder (used for pulmonary arterial hypertension or PAH treatment), provided a significant boost to this penny stock. What’s Next? Liquidia highlighted that the addressable market for inhaled treprostinil is large and will likely expand in the future, which augurs well for its growth.